Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group

Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group

urpose: The medium-risk (IR) prostate cancer (PCa) are a heterogeneous group in terms of prognosis. For unfavorable or favorable IR PCa treated with radiotherapy, the remnants of the optimal strategy to be defined. In routine practice, doctor’s decision to propose hormonal therapy (HT) is controversial. PROACT survey aims to evaluate patterns and preferences of daily practice in France at this IR population.

Materials and Methods: A questionnaire was distributed to member web 91 French radiotherapy centers of the Groupe d’Etude des Tumeurs Uro-Genitales (GETUG). The questionnaire included four sections on: (i) specialists who prescribe treatment and multidisciplinary decision (MTD) validation; (Ii) the definition of patient subsets IR; (Iii) the parameters of radiotherapy; (Iv) regarding the practice patterns of cardiovascular (CV) and (iv) a metabolic evaluation. Descriptive presentation of the results is used.

Results: Among the 82 responses (90% of the centers), HT schedule and irradiation techniques validated by a particular board meeting in 54% and 45% of the center, respectively. Three-quarters (76%) of centers identify a subset of patients with IR to specific strategies. The majority of the center considers PSA> 15 (77%) and / or Gleason 7 (4 + 3) (87%) for the definition of IR unfavorable. Overall, 41% of the center is carried out systematically evaluate CV before HT prescription while 61% only consider CV history / status in defining the type of HT. LHRH agonists is often prescribed in both favorable (70%) and unfavorable (98%) patients with IR. Finally, weight loss (80%), metabolic profile (70%) and CV status (77%) of patients considered for follow-up under HT.

Conclusion: To the best of our knowledge, this is the first survey on practices in IR PCa HT. PROACT survey showed that three-quarters of respondents identified a subset of IR-patients in adjusting therapy. CV status of patients considered in guiding decisions HT, duration and type of .

Two professions against two killer diseases: reason, organizations, and the initial experience cardio-oncology services

Background: Cardiovascular disease (CV) is the most common factor affecting the prognosis in cancer patients. Cardio-oncology (CO) service has been developed to solve this problem. The lack of results regarding patient demographics and clinical findings applicable and available data is limited to the services CO evaluate patients undergoing chemotherapy only.

Purpose: To demonstrate initial experience CO service was conducted in a tertiary oncology centers.
Methods: CO Service is designed to include two major domains: general and consulting CO electrotherapy. Patients who are referred to a collection service CO with basic demographics, type of cancer, the reason for referral, cardiac evaluation, and initial clinical results were included in this observational study.
Results: All cancer patients referred to our CO service between March 2016 and December 2019 included in this study. A total of 2,762 (77% female) patients at a mean (SD) age of 62 (12) years referenced (63% on the basis of hospitalization) for public consultation.

The most frequent diagnosis was breast cancer (66%). In 18% of patients, the reason for referral to services CO is the treatment of cancer-related complications CV. A total of 652 patients (515 patients with cardiac implantable electronic device (CIED) eligible for radiotherapy (RT), 48 patients with diagnosed CIEDs by magnetic resonance imaging (MRI), and 89 patients with cancer treated with surgery CIED) were evaluated by a team CO- CIED. During the 5872 session of the RT total, two dangerous interactions and no other complications during MRI and surgery were recorded.

Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group

Diet Association Quality With Survival Among People With Metastatic Colorectal Cancer at the Cancer and Leukemia Group B and the Southwest Oncology 80 405 Experiment

Importance: Diet has been associated with survival in patients with stage I to III colorectal cancer, but the data in patients with metastatic colorectal cancer are limited.
Objective: To examine the relationship between diet quality and overall survival among individuals with metastatic colorectal cancer.

Design, setting, and participants: This study is a prospective cohort study of patients with metastatic colorectal cancer enrolled in the Cancer and Leukemia Group B (Alliance) and the Southwest Oncology Group 80 405 trials between 27 October 2005 and 29 February 2012, and followed up through January 2018 ,
Exposure: Participants completed a validated food frequency questionnaire within 4 weeks after starting first-line treatment for metastatic colorectal cancer. Diet categorized according to the Alternative Healthy Eating Index (AHEI), Alternative Mediterranean Diet (AMED) score, diet Approaches to Stop Hypertension (DASH) score, and Western and prudent dietary pattern derived using principal component analysis. Participants were classified into sex-specific quintiles.

The main results and measures: multivariable hazard ratio (HR) and 95% CI for overall survival.

Recombinant Human KDR/VEGFR-2/FLK-1(C-6His)

CB26-1mg 1mg
EUR 2983.2
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human KDR/VEGFR-2/FLK-1(C-6His)

CB26-500ug 500ug
EUR 1935.6
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human KDR/VEGFR-2/FLK-1(C-6His)

CB26-50ug 50ug
EUR 595.2
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Human FLT-4/VEGFR-3 control/blocking peptide #2

FLT42-P 100 ug
EUR 196.8

Mouse Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 ELISA kit

CSB-E04764m-24T 1 plate of 24 wells
EUR 198
Description: Quantitative sandwich ELISA kit for measuring Mouse Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Mouse Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 ELISA kit

1-CSB-E04764m
  • EUR 843.60
  • EUR 5811.60
  • EUR 3084.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitative sandwich ELISA kit for measuring Mouse Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Mouse Vascuoar endothelial cell growth factor receptor 2((VEGFR-2/Flk-1)ELISA Kit

GA-E0681MS-48T 48T
EUR 403.2

Mouse Vascuoar endothelial cell growth factor receptor 2((VEGFR-2/Flk-1)ELISA Kit

GA-E0681MS-96T 96T
EUR 640.8

Mouse Vascuoar endothelial cell growth factor receptor 2,(VEGFR-2/Flk-1)ELISA Kit

YLA0973MO-48T 48T
EUR 465

Mouse Vascuoar endothelial cell growth factor receptor 2,(VEGFR-2/Flk-1)ELISA Kit

YLA0973MO-96T 96T
EUR 600

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, unlabeled

AP-336-U 5 mg Ask for price

ELISA kit for Mouse Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE71214-48T 48T
EUR 398.4
Description: Quantitative sandwich ELISA for measuring Mouse Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Mouse Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE71214-5platesof96wells 5 plates of 96 wells
EUR 2538
Description: Quantitative sandwich ELISA for measuring Mouse Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Mouse Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE71214-96T 96T
EUR 646.8
Description: Quantitative sandwich ELISA for measuring Mouse Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, Biotinylated

AP-336-B 1 mg Ask for price

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled

AP-336-F 1 mg Ask for price

Rat Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 ELISA kit

CSB-E07348r-24T 1 plate of 24 wells
EUR 198
Description: Quantitativesandwich ELISA kit for measuring Rat Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Rat Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 ELISA kit

1-CSB-E07348r
  • EUR 843.60
  • EUR 5811.60
  • EUR 3084.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Rat Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Vascuoar endothelial cell growth factor receptor 2,VEGFR-2/Flk-1 ELISA kit

201-12-0248 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 ELISA kit

CSB-E04763h-24T 1 plate of 24 wells
EUR 198
Description: Quantitative sandwich ELISA kit for measuring Human Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 ELISA kit

1-CSB-E04763h
  • EUR 722.40
  • EUR 5085.60
  • EUR 2707.20
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitative sandwich ELISA kit for measuring Human Vascular endothelial cell growth factor receptor 2, VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Vascuoar endothelial cell growth factor receptor 2(VEGFR-2/Flk-1)ELISA Kit

GA-E0264HM-48T 48T
EUR 346.8

Human Vascuoar endothelial cell growth factor receptor 2(VEGFR-2/Flk-1)ELISA Kit

GA-E0264HM-96T 96T
EUR 559.2

Human Vascuoar endothelial cell growth factor receptor 2(VEGFR-2/Flk-1)ELISA Kit

QY-E00704 96T
EUR 433.2

Rabbit Vascuoar endothelial cell growth factor receptor 2(VEGFR-2/Flk-1)ELISA Kit

YLA0001RB-48T 48T
EUR 465

Rabbit Vascuoar endothelial cell growth factor receptor 2(VEGFR-2/Flk-1)ELISA Kit

YLA0001RB-96T 96T
EUR 600

Human Vascuoar endothelial cell growth factor receptor 2,VEGFR-2/Flk-1 ELISA kit

YLA0804HU-48T 48T
EUR 435

Human Vascuoar endothelial cell growth factor receptor 2,VEGFR-2/Flk-1 ELISA kit

YLA0804HU-96T 96T
EUR 562.5

ELISA kit for Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE100727-48T 48T
EUR 457.2
Description: Quantitative sandwich ELISA for measuring Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE100727-5platesof96wells 5 plates of 96 wells
EUR 3194.4
Description: Quantitative sandwich ELISA for measuring Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE100727-96T 96T
EUR 802.8
Description: Quantitative sandwich ELISA for measuring Rat Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE61925-48T 48T
EUR 398.4
Description: Quantitative sandwich ELISA for measuring Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE61925-5platesof96wells 5 plates of 96 wells
EUR 2538
Description: Quantitative sandwich ELISA for measuring Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1)

KTE61925-96T 96T
EUR 646.8
Description: Quantitative sandwich ELISA for measuring Human Vascular endothelial cell growth factor receptor 2 (VEGFR-2/Flk-1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Human Vascular endothelial cell growth factor receptor 2,VEGFR-2/Flk-1

EK0298 96 tests
EUR 854.4
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Vascular endothelial cell growth factor receptor 2,VEGFR-2/Flk-1 in samples from serum, plasma, tissue homogenates and other biological fluids.

VEGFR1 Peptide (OVA)

20-abx165607
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCA0657-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), APC conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCA0721-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), APC conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC800657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC800657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC800721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC800721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC810657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC810657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC810721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC810721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC940657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC940657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC940721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC940721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC700657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC700657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC700721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC700721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC880657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC880657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC880721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC880721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC050721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC050721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC040657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC040657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC040721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC040721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC400657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC400657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC400721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC400721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC050657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC050657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCB0657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCB0657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCB0721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCB0721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCAP0657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCAP0657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCAP0721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCAP0721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCR0657-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), RPE conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCR0721-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), RPE conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCP0657-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), PerCP conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCP0721-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), PerCP conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNUM0657-50 50uL
EUR 474
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), 1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNUM0721-50 50uL
EUR 474
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), 1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCH0657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNCH0657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCH0721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNCH0721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNUB0657-100 100uL
EUR 250.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Concentration: 0.2mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNUB0657-500 500uL
EUR 549.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), Concentration: 0.2mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNUB0721-100 100uL
EUR 250.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Concentration: 0.2mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNUB0721-500 500uL
EUR 549.6
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), Concentration: 0.2mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC550657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC550657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC550721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC550721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC610657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC610657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC610721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC610721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC680657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC680657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC470657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC470657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC470721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC470721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC430657-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR657) Antibody

BNC430657-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR657), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC430721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC430721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC680721-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR2 / Flk-1 / KDR3 / CD309(KDR721) Antibody

BNC680721-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR2 / Flk-1 / KDR3 / CD309(KDR721), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR1 Blocking Peptide

AF7748-BP 1mg
EUR 234

VEGFR3 Blocking Peptide

AF4201-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

AF6204-BP 1mg
EUR 234

VEGFR2 Blocking Peptide

AF6279-BP 1mg
EUR 234

VEGFR2 Blocking Peptide

AF6281-BP 1mg
EUR 234

VEGFR3 Blocking Peptide

DF2689-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

20-abx161622
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR1 Blocking Peptide

20-abx161858
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161912
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161913
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161915
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

Mouse VEGFR-1/Flt1 ELISA Kit

EMV0045 96Tests
EUR 625.2

anti- VEGFR-1/FLT-1 antibody

FNab09393 100µg
EUR 606.3
Description: Antibody raised against VEGFR-1/FLT-1

Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure

FLT12-M 100 ug
EUR 578.4

Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure

FLT14-M 100 ug
EUR 578.4

VEGFR2 (pY951) Blocking Peptide

20-abx161914
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

VEGFR1 (pY1213) Blocking Peptide

20-abx062629
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

VEGFR2 (pY1214) Blocking Peptide

20-abx061614
  • EUR 360.00
  • EUR 594.00
  • 1 mg
  • 5 mg

VEGFR2 (pY1175) Blocking Peptide

20-abx162540
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

VEGFR-1 Antibody

48347-100ul 100ul
EUR 399.6

Results: In a cohort study of 1284 individuals with metastatic colorectal cancer, the median age was 59 (interquartile range [IQR]: 51-68) years, body mass index, the average was 27.2 (IQR, 24.1 to 31, 4), 521 (41%) were women, and in 1102 (86%) were white. There are 1100 deaths during a median follow-up of 73 months (IQR, 64-87 months). We observed an inverse relationship between a score of AMED and the risk of death (HR quintile 5 vs first quintile, 0.83; 95% CI, 0.67 to 1.04; P = 0.04 for trend), but the estimate is not statistically significant point , None of the other diet or pattern values ​​associated with overall survival.

Conclusion and relevance: In this prospective analysis of patients with metastatic colorectal cancer, diet quality were assessed at start of first-line treatment for metastatic disease was not associated with overall survival.

Related Posts

Leave a Reply

Your email address will not be published.